Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3310 - Efficacy of panitumumab and cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): retrospective analysis of data from nationwide Drug-Reimbursement-Access Program

Date

09 Sep 2017

Session

Poster display session

Presenters

Marcin Swierkowski

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

M. Swierkowski1, A. Ptak-Chmielewska2, A. Sliwczynski3, T. Czeleko3, Z. Teter3, C. Szczylik4

Author affiliations

  • 1 Department Of Oncology, Military Insitute of Medicine, 04-141 - Warsaw/PL
  • 2 Institute Of Statistics And Demography, Warsaw School of Economics, Warsaw/PL
  • 3 Warsaw, National Health Fund, Warsaw/PL
  • 4 Department Of Oncology, Military Insitute of Medicine, Warsaw/PL
More

Resources

Abstract 3310

Background

Panitumumab and cetuximab are standards of treatment for chemotherapy-refractory, wild-type KRAS exon 2 mCRC patients. There are limited data on efficacy of these drugs in everyday practice on national level.

Methods

Patients enrolled into nationwide Panitumumab/Cetuximab Reimbursement-Access Program ongoing in Polish cancer centres. All reported patients were included to analyses from April 2012 to December 2015. Key inclusion criteria to the program: mCRC, refractory to chemotherapy (5FU, oxaliplatin, irinotecan), wild-type KRAS exon 2 tumour status, measurable disease, ECOG performance status 0-2. Inclusion and exclusion criteria were the same for panitumumab and cetuximab therapy in all centres. Pre-planned, uniform schedule of efficacy assessment (every 12 weeks) was applied from start of therapy in all centres. Individual patients data concerning efficacy outcome measures were entered prospectively via electronic system into databases of public, national payer - National Health Fund (NFZ). We performed retrospective analysis using Kaplan-Meier method to assess overall survival (OS) and progression-free survival (PFS). Objective response rate (ORR) was also reported.

Results

As of April 2012, 2425 patients were enrolled into the program in 62 cancer centres (1527 patients received panitumumab and 898 received cetuximab). Median follow-up was 17.9 months for panitumumab and 25.3 months for cetuximab. Median OS was 9.9 months (95% CI 9.4-10.5) with panitumumab and 10.2 months with cetuximab (95% CI 9.5-10.9). There was no OS significant difference between groups (p = 0.09). Median PFS was 5.6 months (95% CI 5.5-5.7) with panitumumab (n = 1124) and 5.2 months (95% CI 4.9-5.4) with cetuximab (n = 619). There was no PFS difference between groups (p = 0.16). ORR was 16% in panitumumab and 13% in cetuximab group.

Conclusions

Panitumumab and Cetuximab provide similar efficacy outcomes in everyday practice in one health care system. Reimbursement, centralized drug-access programs may serve as a source of data for survival analysis on national level.

Clinical trial identification

Legal entity responsible for the study

Military Institute of Medicine, Warsaw National Health Fund, Poland

Funding

None

Disclosure

M. Swierkowski: Consulting role with Pfizer. C. Szczylik: Consulting role with Bayer, Pfizer, Ipsen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings